ClariTrial | Search Clinical Trials

Phase 2Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants44 sites · United States, Australia, ChinaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

Compare CT.gov Full analysis →

1–5 of 5

Explore/PROTAC degrader

Status

Phase

5 results for “PROTAC degrader”

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Solid TumorAdvanced Solid TumorSolid Tumor, Adult

NKT3964

NiKang Therapeutics, Inc.150 participants19 sites · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Active

Results posted

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Phase 3Advanced Breast Cancer

ARV-471Fulvestrant

Pfizer624 participants312 sites · United States, Argentina, AustraliaCompletes Jan 2025

Compare CT.gov Full analysis →

Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer

DT2216Paclitaxel

Elizabeth Stover, MD, PhD30 participants3 sites · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 2Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants44 sites · United States, Australia, ChinaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

Compare CT.gov Full analysis →

1–5 of 5